Allergen Immunotherapy
Key Points
- Allergen immunotherapy is an adjunct option when trigger avoidance is not feasible and allergy history/testing supports a specific allergen target.
- Treatment goals include lowering circulating IgE effect, increasing blocking IgG activity, and reducing mediator-cell hypersensitivity.
- Major delivery pathways are subcutaneous (SIT), epicutaneous (EPIT), and sublingual (SLIT).
- SIT requires post-dose observation for systemic reactions, including anaphylaxis risk.
- Clinical benefit is gradual and may require years of adherence.
Pathophysiology
Allergen immunotherapy progressively exposes the immune system to controlled allergen doses to shift reactivity away from severe immediate-response patterns. Over time, this can reduce symptom severity and medication burden in selected IgE-mediated disease pathways.
Treatment success depends on accurate allergen identification, adequate dosing progression, and sustained adherence. If symptom burden, tolerance, and medication reduction do not improve over follow-up, therapeutic failure should be reassessed.
Classification
- SIT (Subcutaneous Immunotherapy): Serial allergen-extract injections with gradual dose escalation to maintenance, then booster intervals.
- EPIT (Epicutaneous Immunotherapy): Allergen delivery through epidermal pathway with generally lower systemic-reaction risk than injection pathways.
- SLIT (Sublingual Immunotherapy): Allergen liquid/tablet administered under the tongue after buildup, typically in repeated outpatient/home schedules.
Nursing Assessment
NCLEX Focus
Prioritize reaction-risk screening and post-administration monitoring safety before discharge from immunotherapy visits.
- Confirm allergy history, test correlation, and inability to adequately avoid confirmed triggers.
- Assess pregnancy status before initiation; do not start new immunotherapy during pregnancy.
- For ongoing pregnancy in previously established therapy, verify that dose-escalation is not occurring.
- Monitor for local and systemic reactions after administration (for example swelling, urticaria, dyspnea, hypotension).
- During SIT visits, observe for at least 30 minutes for delayed severe-reaction cues.
Nursing Interventions
- Reinforce long-horizon adherence expectations (often multi-year therapy; commonly 3-5 years).
- Educate patients that large local swelling after SIT should be reported before next dose escalation.
- Keep emergency-response supplies available in immunotherapy settings and escalate anaphylaxis cues immediately.
- For SLIT pathways, teach expected mild oral/GI adverse effects and return precautions for systemic symptoms.
- Reassess effectiveness periodically; escalate provider review if no meaningful response or medication-sparing benefit is achieved.
Reaction-Risk Safety
Systemic reactions are uncommon but possible in all pathways; do not dismiss early respiratory or hemodynamic symptoms after dosing.
Clinical Judgment Application
Clinical Scenario
A patient with persistent seasonal allergic disease has positive skin testing and ongoing symptoms despite trigger-reduction and medication adherence.
- Recognize Cues: Confirmed allergen sensitivity plus uncontrolled symptoms under standard management.
- Analyze Cues: Pattern supports candidate status for desensitization strategy.
- Prioritize Hypotheses: Priority is balancing long-term symptom reduction against systemic-reaction risk.
- Generate Solutions: Coordinate route-specific plan (SIT/EPIT/SLIT), safety monitoring, and adherence education.
- Take Action: Implement ordered therapy with observation, reaction surveillance, and reinforcement of follow-up.
- Evaluate Outcomes: Symptom burden and rescue-medication needs decrease without serious adverse events.
Related Concepts
- allergic-rhinitis - Common clinical context where immunotherapy is considered.
- hypersensitivity-types-and-anaphylaxis-response - IgE-mediated pathway and severe-reaction framework.
- anaphylaxis - Emergency escalation pathway for severe systemic reactions.
- antihistamines - Adjunct symptomatic control during long-term desensitization plans.
- decongestants - Short-course symptomatic relief while long-term therapy takes effect.
Self-Check
- Which findings indicate appropriate candidate selection for allergen immunotherapy?
- Why is post-SIT observation mandatory even when prior doses were tolerated?
- What reassessment cues suggest therapeutic failure and need for plan revision?